Preimplantation genetic diagnosis

Genetic Testing Market to Reach $28.24 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Meticulous Research®

Retrieved on: 
Monday, March 20, 2023
Glaucoma, DNA, Ventricular septal defect, Prevalence, Impact, Viral Research and Diagnostic Laboratories, Parent, Hospital, Pharmacogenomics, COVID-19, Cancer, Down syndrome, Genetic testing, Diagnosis, Genomics, Hemoglobinopathy, Disorder, Government, PerkinElmer, Fragile X syndrome, MUFG Americas Holdings Corporation, Thermo Fisher Scientific, Patient, Laboratory, Risk, Developed country, Preimplantation genetic diagnosis, Investment, Labcorp, Consumables, Cystic fibrosis, Carrier, Hospital Clinic Manuel Quintela, Association for Molecular Pathology v. Myriad Genetics, Inc., Rare, Illumina, Inc., Geography, Pharmaceutical industry, Dietary supplement, Chromosome, Prenatal development

Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.

Key Points: 
  • Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.
  • Genetic testing is performed for different reasons, including pre-symptomatic and predictive testing, pharmacogenetics, diagnostic testing, carrier testing, prenatal testing, preimplantation testing, and newborn screening.
  • Genetic testing has applications in different areas of healthcare and has various advantages, such as determining the likelihood of parents passing the genetic mutation to their offspring.
  • Quick Buy – Genetic Testing Market Research Report: https://www.meticulousresearch.com/Checkout/33822956
    Based on end user, in 2023, the hospitals & clinics segment is expected to account for the largest share of this market.

Genetic Testing Market to Reach $28.24 Billion by 2030 - Market Size, Share, Forecasts, & Trends Analysis Report by Meticulous Research®

Retrieved on: 
Monday, March 20, 2023
Glaucoma, DNA, Ventricular septal defect, Prevalence, Impact, Viral Research and Diagnostic Laboratories, Parent, Hospital, Pharmacogenomics, COVID-19, Cancer, Down syndrome, Genetic testing, Diagnosis, Genomics, Hemoglobinopathy, Disorder, Government, PerkinElmer, Fragile X syndrome, MUFG Americas Holdings Corporation, Thermo Fisher Scientific, Patient, Laboratory, Risk, Developed country, Preimplantation genetic diagnosis, Investment, Labcorp, Consumables, Cystic fibrosis, Carrier, Hospital Clinic Manuel Quintela, Association for Molecular Pathology v. Myriad Genetics, Inc., Rare, Illumina, Inc., Geography, Pharmaceutical industry, Dietary supplement, Chromosome, Prenatal development

Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.

Key Points: 
  • Genetic testing is done to look at changes in the DNA, sometimes called variants or mutations, that can lead to chronic diseases.
  • Genetic testing is performed for different reasons, including pre-symptomatic and predictive testing, pharmacogenetics, diagnostic testing, carrier testing, prenatal testing, preimplantation testing, and newborn screening.
  • Genetic testing has applications in different areas of healthcare and has various advantages, such as determining the likelihood of parents passing the genetic mutation to their offspring.
  • Quick Buy – Genetic Testing Market Research Report: https://www.meticulousresearch.com/Checkout/33822956
    Based on end user, in 2023, the hospitals & clinics segment is expected to account for the largest share of this market.

Outlook on the Assisted Reproductive Technology Global Market to 2030 - Featuring Cosmos Biomedical, CooperSurgical and Ferring Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, October 7, 2022
Other Health, Men, General Health, Family, Consumer, Hospitals, Children, Surgery, Baby, Maternity, Women, Biotechnology, Health, Adoption, Fertility clinic, Insemination, PGD, Cryopreservation, Government, Growth, American Society for Reproductive Medicine, Sun Pharma, CAGR, Reproductive medicine, Society, Relaxation, Research, Machine learning, Mental health, National library, Reproductive technology, Ganirelix, Preimplantation genetic diagnosis, Industry, Artificial insemination, Ferring Pharmaceuticals, Awareness, SART, Assisted reproductive technology, IVF, United States National Library of Medicine, Artificial intelligence, Hospital, Infertility, Child, COVID-19, USD, Medical device, Birth control, ART

The global assisted reproductive technology market size is expected to reach USD 41.4 billion by 2030, according to this report.

Key Points: 
  • The global assisted reproductive technology market size is expected to reach USD 41.4 billion by 2030, according to this report.
  • The growth of the market is mainly driven by the rising cases of infertility globally.
  • The rising adoption of Assisted Reproductive Technologies (ART) by couples and prospective parents trying for children is expected to boost the industry's growth.
  • Key companies operating in the market are adopting various strategies to gain higher market share, such as mergers and acquisitions.

Global In Vitro Fertilization (IVF) Market 2022-2027: Rising Cases of Infertility & Government Initiatives to Promote IVF Treatments Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, August 29, 2022
Baby, Maternity, Health, Consumer, Other Health, Instrument, Market development, Observation, Global environmental analysis, Fertility clinic, Porter's five forces analysis, USD, Ansoff Matrix, IVF, Investment, Geography, SWOT, CAGR, Hospital, Micromanipulator, Risk, COVID-19, Growth, Preimplantation genetic diagnosis, Industry, Music instrument technology, Medical device, Retail, Risk management, Incubator, Technology

The Global In Vitro Fertilization (IVF) Market is segmented based on Instrument, Technology, End-User, and Geography.

Key Points: 
  • The Global In Vitro Fertilization (IVF) Market is segmented based on Instrument, Technology, End-User, and Geography.
  • By Instrument, the market is classified into Cabinet, Incubators, Micromanipulator, Ovum Aspiration Pump, and Sperm Aspiration Pump.
  • The report presents a detailed Ansoff matrix analysis for the Global In Vitro Fertilization (IVF) Market.
  • The report offers a comprehensive evaluation of the Global In Vitro Fertilization (IVF) Market.

Mikrogen and Phosphorus Announce Partnership to Provide Holistic, Preventative Genetic Insights to Reproductive Health Services in Turkey.

Retrieved on: 
Thursday, February 24, 2022
Genetics, Health, Partnership, Pharmacogenomics, Accreditation, European, Degenerative disease, Preimplantation genetic diagnosis, Diet, Diet (nutrition), Hearing loss, University, Kinesiogenomics, Severe cognitive impairment, Chromosome, Sibling, Organization, Medicine, Genetic testing, Cancer, Exercise, Genomics, Endocrinology, Multimedia, Private, Science, Infertility, HLA, Sleep, Patient, Reproductive medicine, Neurology, State, Solution, CEO, Software, Agriculture, Antibiotics, Phosphorus

For over 20 years, Mikrogen Genetic Diseases Diagnosis Center has delivered reproductive medicine and embryo genetics services.

Key Points: 
  • For over 20 years, Mikrogen Genetic Diseases Diagnosis Center has delivered reproductive medicine and embryo genetics services.
  • "We are excited to have the Mikrogen team as our partner in preventative genetic testing in the Middle East," said Alex Bisignano, Founder and CEO of Phosphorus.
  • "We believe the medical-grade depth and accuracy of GeneCompass provides critical information and will seamlessly augment the services Mikrogen already provides."
  • Additionally, Phosphorus provides white-labeling genomics-as-a-service solutions by partnering with organizations who want to deploy their own preventative genetic testing solutions.

IVF Life the first clinic group in Europe to use Artificial Intelligence to non-invasively assess the genetic integrity of embryos

Retrieved on: 
Tuesday, May 25, 2021
Reproduction, Human reproduction, Fertility medicine, Branches of biology, Cryobiology, Fertility, In vitro fertilisation, Obstetrics, Embryo, Assisted reproductive technology, Preimplantation genetic diagnosis

ADELAIDE, Australia, May 25, 2021 /PRNewswire/ --IVF Life Group, a leading group of IVF clinics across Spain, UK, and Germany, will be among the first in Europe to use Artificial Intelligence (AI) to non-invasively assess embryos to determine their genetic integrity.

Key Points: 
  • ADELAIDE, Australia, May 25, 2021 /PRNewswire/ --IVF Life Group, a leading group of IVF clinics across Spain, UK, and Germany, will be among the first in Europe to use Artificial Intelligence (AI) to non-invasively assess embryos to determine their genetic integrity.
  • The AI product Life Whisperer, developed by global healthcare company Presagen, uses images of embryos to assess their quality to assist with embryo selection, and ultimately improve IVF outcomes for patients.
  • Life Whisperer Genetics, which this month received CE Mark in Europe, requires only standard camera images of embryos to assess their genetic integrity.
  • Founder & President of IVF Life Group, Dr. Jon Aizpurua said "For the next two months, IVF Life will offer all patients, at no additional cost, the use of both Life Whisperer Genetics and Life Whisperer Viability.

IVF Life the first clinic group in Europe to use Artificial Intelligence to non-invasively assess the genetic integrity of embryos

Retrieved on: 
Tuesday, May 25, 2021
Reproduction, Human reproduction, Fertility medicine, Branches of biology, Cryobiology, Fertility, In vitro fertilisation, Obstetrics, Embryo, Assisted reproductive technology, Preimplantation genetic diagnosis

ADELAIDE, Australia, May 25, 2021 /PRNewswire/ --IVF Life Group, a leading group of IVF clinics across Spain, UK, and Germany, will be among the first in Europe to use Artificial Intelligence (AI) to non-invasively assess embryos to determine their genetic integrity.

Key Points: 
  • ADELAIDE, Australia, May 25, 2021 /PRNewswire/ --IVF Life Group, a leading group of IVF clinics across Spain, UK, and Germany, will be among the first in Europe to use Artificial Intelligence (AI) to non-invasively assess embryos to determine their genetic integrity.
  • The AI product Life Whisperer, developed by global healthcare company Presagen, uses images of embryos to assess their quality to assist with embryo selection, and ultimately improve IVF outcomes for patients.
  • Life Whisperer Genetics, which this month received CE Mark in Europe, requires only standard camera images of embryos to assess their genetic integrity.
  • Founder & President of IVF Life Group, Dr. Jon Aizpurua said "For the next two months, IVF Life will offer all patients, at no additional cost, the use of both Life Whisperer Genetics and Life Whisperer Viability.

Artificial Intelligence helps IVF patients avoid invasive embryo genetic testing

Retrieved on: 
Thursday, April 29, 2021
Reproduction, Branches of biology, Fertility medicine, Human reproduction, Cryobiology, Fertility, Human pregnancy, Obstetrics, In vitro fertilisation, Miscarriage, Embryo, Preimplantation genetic diagnosis

PGT-A testing is conducted because evidence suggests genetically healthy embryos can increase pregnancy success and reduce miscarriage for IVF patients who are desperate for children.

Key Points: 
  • PGT-A testing is conducted because evidence suggests genetically healthy embryos can increase pregnancy success and reduce miscarriage for IVF patients who are desperate for children.
  • "\nPresagen\'s new AI product, Life Whisperer Genetics, requires only camera images of embryos to assess their genetic integrity.
  • Here in the USA where PGT-A testing is common, Life Whisperer Genetics would provide the opportunity to pre-screen and only test the healthiest and most viable embryos, reducing costs for our patients.
  • "\nPresagen plans to build additional healthcare products, both in IVF and beyond, initially focusing on women\'s health.\n'

Artificial Intelligence helps IVF patients avoid invasive embryo genetic testing

Retrieved on: 
Thursday, April 29, 2021
Reproduction, Branches of biology, Fertility medicine, Human reproduction, Cryobiology, Fertility, Human pregnancy, Obstetrics, In vitro fertilisation, Miscarriage, Embryo, Preimplantation genetic diagnosis

PGT-A testing is conducted because evidence suggests genetically healthy embryos can increase pregnancy success and reduce miscarriage for IVF patients who are desperate for children.

Key Points: 
  • PGT-A testing is conducted because evidence suggests genetically healthy embryos can increase pregnancy success and reduce miscarriage for IVF patients who are desperate for children.
  • "\nPresagen\'s new AI product, Life Whisperer Genetics, requires only camera images of embryos to assess their genetic integrity.
  • Here in the USA where PGT-A testing is common, Life Whisperer Genetics would provide the opportunity to pre-screen and only test the healthiest and most viable embryos, reducing costs for our patients.
  • "\nPresagen plans to build additional healthcare products, both in IVF and beyond, initially focusing on women\'s health.\n'

Orchid Launches Reports to Help Couples Have Healthy Babies By Quantifying Genetic Risk

Retrieved on: 
Wednesday, April 7, 2021
Reproduction, Fertility medicine, Branches of biology, Human reproduction, Cryobiology, Fertility, In vitro fertilisation, Obstetrics, Embryo, Preimplantation genetic diagnosis, Embryo donation

Orchid detects if a couple's future child will be at elevated or normal genetic risk to top diseases.

Key Points: 
  • Orchid detects if a couple's future child will be at elevated or normal genetic risk to top diseases.
  • During IVF, embryos are created, and later this year, Orchid will offer an Embryo Report for couples interested in mitigating genetic risk to disease.
  • Orchid makes it possible to minimize the risk of developing disease by quantifying previously unknown genetic risks and personalized guidance around lifestyle changes.
  • Couples with elevated risk can elect to pursue IVF, and mitigate risk through follow-up embryo health reports.